Good morning. Elizabeth Cooney here in STAT’s Boston HQ, collaborating with Ed Silverman in San Francisco, where he has joined STAT’s corps of reporters covering the J.P. Morgan Healthcare Conference (or, as Ed refers to it, the annual Woodstock gathering for biopharma types). Here’s what we’re watching today, starting with that meeting:

A year after STAT found more men named Michael than female CEOs giving corporate presentations at the J.P. Morgan Healthcare Conference, the tables have turned, STAT reports. At this week’s confab, there will be 33 female CEOs presenting corporate updates, compared to 19 men named Michael. And yet women will still be massively outnumbered on one of biotech’s biggest stages: Men represent 90 percent of the 553 executives who will give corporate presentations at JPM. That’s down from 94 percent last year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Talk about inflation … for drug prices?! Only in America would $8 Billion (with a ‘B’) describe the sale price for “a tiny company.” (Cf Lilly purchase of Loxo mentioned above)

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy